Can a common blood thinner be safe for ICU patients with liver issues?

NCT ID NCT07751874

Not yet recruiting Knowledge-focused Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study looks at whether a blood-thinning method called citrate anticoagulation is safe and practical for critically ill patients with acute kidney injury who may not process citrate normally. It follows 50 ICU patients who need kidney replacement therapy and are at risk for citrate buildup. The goal is to see how often citrate toxicity occurs and whether this approach can be used without causing harm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: continuous renal replacement therapy with regional citrate anticoagulation
What this could lead to: If successful, this could support the safe use of citrate anticoagulation in patients with impaired citrate metabolism, potentially expanding treatment options for acute kidney injury in the ICU.
What could go wrong: This is an observational study with a small sample size, and it does not compare against other treatments. The risk of citrate toxicity remains a concern, and results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

Contacts and locations

Locations

Antwerp University Hospital

Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.